共 969 条
[1]
Ishida Y(1992)Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death EMBO J 11 3887-3895
[2]
Agata Y(2000)Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation J Exp Med 192 1027-1034
[3]
Shibahara K(2001)PD-L2 is a second ligand for PD-1 and inhibits T cell activation Nat Immunol 2 261-268
[4]
Honjo T(2007)Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses Immunity 27 111-122
[5]
Freeman GJ(2010)B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance Blood 116 1291-8
[6]
Long AJ(2015)PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma N Engl J Med 372 311-319
[7]
Iwai Y(2016)Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure J Clin Oncol 34 3733-3739
[8]
Bourque K(2016)Pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: long term efficacy from phase Ib Keynote-013 study Blood 128 1108-1294
[9]
Chernova T(2016)Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial Lancet Oncol 17 1283-136
[10]
Nishimura H(2017)Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow-up of the phase 2 CHECKMATE 205 trial Hematol Oncol 35 135-2132